Literature DB >> 28554416

Treatment of Older Parkinson's Disease.

Abhishek Lenka1, Chandrasekharapillai Padmakumar2, Pramod K Pal3.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. The prevalence of PD increases with age. The spectrum of clinical features, the rate of progression of the disease, the burden of nonmotor symptoms, and the response to medications are different in older patients with PD from the relatively younger patients. Management of symptoms of PD in older patients is challenging because of possible existence of several age-related systemic illness. While dealing with older patients, it is crucial not to attribute all the physical symptoms to PD. Thorough evaluation for existence of diseases such as normal pressure hydrocephalus and vascular parkinsonism which partially mimic the symptoms of PD carries immense importance. Medical management of parkinsonian symptoms should be preferred with levodopa monotherapy. However, in patients with significant motor fluctuations, dopaminergic agents may be added with caution, as they are notorious for several adverse reactions. Nonmotor symptoms must be provided high importance as they substantially worsen the quality of life. In addition to parkinsonian symptoms, older patients with PD may need to undergo surgery for several conditions. Meticulous perioperative management is crucial as older patients with PD may face several surgery-related complications compared to the younger patients. Compliance to treatment is an important issue in old age. Hence multidisciplinary approach to management of PD in older patients should be emphasized.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Geriatrics; Old age; Older Parkinson's disease; Parkinson's disease

Mesh:

Substances:

Year:  2017        PMID: 28554416     DOI: 10.1016/bs.irn.2017.01.005

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  5 in total

1.  Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All.

Authors:  Lauren E Ryden; Simon J G Lewis
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

2.  Overexpression of MicroRNA-133a Inhibits Apoptosis and Autophagy in a Cell Model of Parkinson's Disease by Downregulating Ras-Related C3 Botulinum Toxin Substrate 1 (RAC1).

Authors:  Wusheng Lu; Jinhuang Lin; Dequan Zheng; Chunyong Hong; Laishun Ke; Xinyu Wu; Peineng Chen
Journal:  Med Sci Monit       Date:  2020-07-27

3.  Overexpression of microRNA-183 promotes apoptosis of substantia nigra neurons via the inhibition of OSMR in a mouse model of Parkinson's disease.

Authors:  Jin-Xia Gao; Yu Li; Sai-Nan Wang; Xing-Chi Chen; Lu-Lu Lin; Hui Zhang
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

Review 4.  An Innovative Personalised Management Program for Older Adults with Parkinson's Disease: New Concepts and Future Directions.

Authors:  Piyush Varma; Lakshanaa Narayan; Jane Alty; Virginia Painter; Chandrasekhara Padmakumar
Journal:  J Pers Med       Date:  2021-01-14

Review 5.  Could Small Heat Shock Protein HSP27 Be a First-Line Target for Preventing Protein Aggregation in Parkinson's Disease?

Authors:  Javier Navarro-Zaragoza; Lorena Cuenca-Bermejo; Pilar Almela; María-Luisa Laorden; María-Trinidad Herrero
Journal:  Int J Mol Sci       Date:  2021-03-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.